Lenco Diagnostic Laboratories,inc.

Lenco Diagnostic Laboratories,inc. was paid $105.14M by Medicaid between Jan 2018 and Feb 2024, across 320 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 24% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#5 of 116

Median peer was paid$618K

This provider vs. median170×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	869,124	$8.49M
2019	1,102,377	$10.22M
2020	1,436,319	$19.93M
2021	2,044,889	$29.31M
2022	1,903,576	$21.75M
2023	1,720,370	$13.93M
2024incomplete	173,459	$1.52M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	24%	336,306	305,346	$25.66M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	5.8%	326,532	325,603	$6.13M
86769		4.9%	151,220	130,878	$5.17M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.7%	231,884	210,878	$4.95M
80050	General health panel	3.6%	193,639	193,283	$3.82M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	2.9%	30,673	30,008	$3.07M
83036	Hemoglobin; glycosylated (A1C)	2.5%	459,376	457,564	$2.66M
86481		2.4%	72,448	72,164	$2.51M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.3%	165,700	164,483	$2.44M
80061	Lipid panel	2.1%	521,251	518,985	$2.23M
80053	Comprehensive metabolic panel	2.0%	379,671	376,092	$2.14M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.9%	143,926	142,922	$2.04M

308 more codes

82607		1.8%	242,093	$1.87M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.5%	6,172	$1.55M
84443	Thyroid stimulating hormone (TSH)	1.4%	271,987	$1.51M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.2%	11,072	$1.27M
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.1%	91,563	$1.15M
82746		1.1%	152,195	$1.11M
84439		<1%	181,009	$990K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	435,896	$975K
81001		<1%	417,732	$863K
84153		<1%	75,189	$855K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	8,886	$842K
88142		<1%	53,860	$731K
86706		<1%	121,638	$729K
87340		<1%	112,320	$714K
84481		<1%	117,555	$703K
86803		<1%	105,043	$688K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	82,413	$686K
82728		<1%	84,143	$679K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	49,417	$677K
83013		<1%	14,510	$665K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	35,751	$637K
84403		<1%	33,574	$578K
86003		<1%	11,662	$559K
86480		<1%	16,178	$545K
82652		<1%	33,967	$510K
86696		<1%	45,280	$497K
87086	Culture, bacterial; quantitative colony count, urine	<1%	100,040	$496K
86762		<1%	51,457	$485K
84378		<1%	60,896	$474K
84154		<1%	40,220	$465K
86765		<1%	51,429	$435K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	20,103	$411K
86708		<1%	62,171	$411K
82043		<1%	125,156	$385K
83540		<1%	126,414	$376K
86703		<1%	48,249	$371K
86704		<1%	60,011	$368K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	12,731	$365K
82570		<1%	124,330	$360K
83655		<1%	42,646	$354K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	9,120	$337K
87592		<1%	15,212	$314K
86695		<1%	42,936	$305K
86592		<1%	134,603	$295K
84436		<1%	123,438	$291K
84550		<1%	102,496	$289K
86702		<1%	28,670	$282K
83001		<1%	22,808	$281K
83002		<1%	21,688	$261K
86735		<1%	46,531	$259K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	7,559	$252K
82248		<1%	82,334	$251K
83550		<1%	100,703	$240K
86787		<1%	40,313	$233K
87522	Neg quan hep c or qual rna	<1%	7,528	$225K
87517		<1%	10,677	$224K
84146		<1%	17,086	$224K
82670		<1%	11,908	$220K
84702		<1%	26,833	$211K
80074		<1%	8,615	$198K
84466		<1%	26,145	$197K
83880		<1%	10,117	$196K
83735		<1%	61,724	$190K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	3,494	$188K
80048	Basic metabolic panel (calcium, ionized)	<1%	39,829	$177K
84402		<1%	11,170	$169K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,192	$167K
84144		<1%	12,370	$166K
83970		<1%	6,446	$163K
88121		<1%	950	$156K
87070		<1%	31,122	$156K
86376		<1%	17,000	$153K
84207		<1%	8,494	$152K
82378		<1%	12,091	$148K
80076		<1%	35,263	$142K
82627		<1%	10,022	$141K
88141		<1%	25,172	$137K
87631		<1%	2,254	$136K
81539		<1%	1,651	$129K
84270		<1%	18,633	$128K
84479		<1%	93,179	$123K
86618		<1%	9,926	$118K
86141		<1%	17,995	$118K
87581		<1%	6,216	$111K
87486		<1%	6,216	$111K
86800		<1%	13,346	$110K
84100		<1%	38,389	$108K
82785		<1%	12,624	$104K
87481		<1%	8,179	$104K
87350		<1%	16,227	$102K
86707		<1%	16,182	$102K
83690		<1%	27,918	$100K
85730		<1%	27,954	$99K
84480		<1%	58,743	$98K
83698		<1%	6,604	$96K
83090		<1%	8,607	$96K
86038		<1%	24,989	$95K
84425		<1%	9,809	$90K
83021		<1%	7,446	$90K
86431		<1%	27,461	$88K
82977		<1%	27,764	$88K
86140		<1%	36,750	$87K
86304		<1%	6,627	$85K
85651		<1%	60,317	$83K
82525		<1%	8,890	$82K
85610		<1%	36,558	$82K
83525		<1%	10,325	$81K
86301		<1%	5,826	$75K
82105		<1%	15,672	$74K
86709		<1%	13,502	$74K
82150		<1%	23,614	$73K
82533		<1%	6,901	$71K
88112		<1%	2,964	$60K
82550		<1%	19,558	$59K
87625		<1%	5,897	$59K
84446		<1%	6,221	$57K
86235		<1%	4,519	$57K
83615		<1%	18,367	$57K
86705		<1%	10,315	$57K
82565		<1%	59,584	$56K
82180		<1%	9,293	$56K
82274		<1%	19,474	$56K
87276		<1%	6,101	$54K
84590		<1%	6,823	$52K
87507		<1%	248	$50K
87275		<1%	6,101	$49K
84681		<1%	3,799	$49K
88120		<1%	392	$48K
82465		<1%	20,547	$45K
88312		<1%	2,179	$45K
82542		<1%	615	$41K
86850		<1%	10,498	$40K
88377		<1%	184	$39K
87536		<1%	688	$38K
86300		<1%	2,094	$37K
82672		<1%	2,536	$37K
86617		<1%	2,293	$36K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	2,048	$34K
86701		<1%	25,089	$34K
86160		<1%	2,891	$33K
84445		<1%	1,772	$31K
87088		<1%	7,035	$30K
84252		<1%	5,477	$29K
82784		<1%	3,555	$29K
87480		<1%	3,535	$27K
86225		<1%	6,478	$26K
86780		<1%	3,157	$25K
87634		<1%	1,609	$25K
84597		<1%	2,554	$24K
85045		<1%	11,810	$24K
83516		<1%	4,056	$24K
83520		<1%	3,865	$23K
86900		<1%	10,731	$23K
86901		<1%	10,724	$23K
88311		<1%	2,464	$22K
85379		<1%	3,596	$21K
87338		<1%	3,721	$21K
84442		<1%	3,347	$21K
86677		<1%	2,864	$20K
86665		<1%	1,158	$20K
81003		<1%	14,239	$18K
83921		<1%	1,441	$18K
86063		<1%	6,642	$18K
84482		<1%	3,899	$18K
86364		<1%	1,035	$16K
86648		<1%	3,824	$16K
86334		<1%	1,021	$16K
86200		<1%	3,315	$15K
82040		<1%	11,195	$15K
87510		<1%	1,568	$14K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	3,209	$14K
87177		<1%	2,255	$14K
86255		<1%	3,257	$13K
82397		<1%	2,418	$13K
87045		<1%	2,361	$12K
86644		<1%	1,258	$12K
84460		<1%	4,198	$12K
86039		<1%	3,159	$12K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	54	$12K
86777		<1%	1,135	$11K
87660		<1%	1,358	$11K
84238		<1%	964	$11K
87511		<1%	809	$11K
86147		<1%	652	$11K
83883		<1%	2,949	$11K
87109		<1%	1,703	$11K
36415	Collection of venous blood by venipuncture	<1%	43,372	$11K
86664		<1%	1,138	$10K
86381		<1%	752	$10K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	322	$10K
84432		<1%	3,039	$10K
84165		<1%	1,769	$10K
86645		<1%	1,644	$10K
87209		<1%	2,259	$10K
84156		<1%	4,277	$9K
80069		<1%	1,658	$9K
82140		<1%	1,044	$9K
85660		<1%	3,893	$9K
82985		<1%	1,301	$9K
86060		<1%	2,879	$9K
84450		<1%	4,114	$8K
88365		<1%	113	$8K
82172		<1%	546	$7K
87150		<1%	612	$7K
87529		<1%	280	$7K
84132		<1%	6,435	$7K
87181		<1%	2,690	$7K
84478		<1%	3,769	$7K
86663		<1%	650	$6K
83704		<1%	465	$6K
84484		<1%	1,141	$6K
81327		<1%	180	$6K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	600	$5K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	3,128	$5K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	65	$5K
84630		<1%	1,050	$5K
81025		<1%	2,608	$5K
86778		<1%	500	$5K
84591		<1%	1,169	$4K
87902		<1%	20	$4K
88342		<1%	140	$4K
82947		<1%	6,760	$4K
86738		<1%	441	$4K
83695		<1%	605	$4K
82310		<1%	2,331	$4K
87101		<1%	734	$4K
84520		<1%	2,631	$4K
82088		<1%	158	$4K
80164		<1%	707	$4K
86360		<1%	93	$4K
83498		<1%	196	$3K
80177		<1%	706	$3K
81596		<1%	100	$3K
86340		<1%	479	$3K
84166		<1%	486	$3K
84075		<1%	1,090	$3K
82272		<1%	1,707	$3K
82553		<1%	614	$3K
86256		<1%	327	$3K
85303		<1%	258	$3K
82610		<1%	468	$3K
80081		<1%	130	$3K
84540		<1%	547	$3K
83718		<1%	1,020	$3K
88313		<1%	130	$2K
83825		<1%	270	$2K
83003		<1%	239	$2K
84305		<1%	169	$2K
86774		<1%	373	$2K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	45	$2K
85301		<1%	223	$2K
87081		<1%	629	$2K
85307		<1%	167	$2K
82552		<1%	281	$2K
86308		<1%	523	$2K
85240		<1%	187	$1K
87623		<1%	827	$1K
84155		<1%	1,010	$1K
82747		<1%	171	$1K
86790		<1%	388	$1K
84560		<1%	415	$1K
81374		<1%	31	$1K
87329		<1%	101	$956.38
84080		<1%	135	$886.32
85032		<1%	9,716	$842.68
86021		<1%	313	$815.06
85613		<1%	126	$751.73
86631		<1%	117	$750.53
84295		<1%	575	$717.24
81007		<1%	722	$614.86
86148		<1%	50	$601.15
86747		<1%	33	$575.38
86162		<1%	72	$568.48
86036		<1%	133	$566.87
86146		<1%	112	$547.90
82247		<1%	159	$519.38
82330		<1%	138	$467.06
80055		<1%	34	$428.85
82376		<1%	136	$420.56
82390		<1%	75	$412.07
80414		<1%	12	$403.82
82705		<1%	120	$399.70
86215		<1%	81	$336.49
87493		<1%	26	$334.73
80178		<1%	90	$292.74
82950		<1%	80	$292.43
83719		<1%	53	$291.17
86341		<1%	26	$273.67
82668		<1%	26	$257.52
84300		<1%	91	$242.37
82157		<1%	14	$223.11
82164		<1%	55	$201.95
86335		<1%	12	$194.23
86632		<1%	30	$156.86
84244		<1%	25	$143.02
82435		<1%	162	$141.11
87116		<1%	25	$132.53
87046		<1%	58	$121.18
83721		<1%	39	$106.28
80051		<1%	49	$79.00
87206		<1%	25	$66.10
87015		<1%	25	$49.81
81000		<1%	16	$26.53
85014		<1%	13	$2.00
3046F		<1%	2,387	$0.61
3044F		<1%	37,693	$0.60
3045F		<1%	396	$0.11
99080		0%	169	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTYLMAN, IRINA (PRESIDENT)